American Association for Cancer Research

Skip to Main Content

Table 2.

Clinical course of individual patients

Patient	After stopping erlotinib or gefitinib	After resuming erlotinib or gefitinib
1	No change	No change
2	Increased cough	Cough stable
3	Seizure, increase in size of brain mets	Brain mets stable
4	No change	No change
5	Increased cough	Cough stable
6	Increased pleural effusion	Improved*
7	No change	No change
8	Cough/fever	Resolution
9	Increased pain	Pain stabilized
10	Increased cough, hemoptysis	Improved cough and hemoptysis
11^†	Liver failure	Death
12^†	Pain/weakness	No change
13^†	Increased fatigue/weakness	Increased pain

Patient	After stopping erlotinib or gefitinib	After resuming erlotinib or gefitinib
1	No change	No change
2	Increased cough	Cough stable
3	Seizure, increase in size of brain mets	Brain mets stable
4	No change	No change
5	Increased cough	Cough stable
6	Increased pleural effusion	Improved*
7	No change	No change
8	Cough/fever	Resolution
9	Increased pain	Pain stabilized
10	Increased cough, hemoptysis	Improved cough and hemoptysis
11^†	Liver failure	Death
12^†	Pain/weakness	No change
13^†	Increased fatigue/weakness	Increased pain

Required drainage of pleural effusion before resumption of gefitinib.

Came off study before completing the first four CT and PET/CT scans.